Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

European research group focuses on TTD non-nucleoside reverse transcriptase inhibitors

Nov. 4, 1998

FDA committee favors accelerated approval of Ziagen

Nov. 3, 1998

Agenerase filed with European regulatory authorities

Nov. 3, 1998

Liposomal GPI-2A associated with unexpected side effects in early clinical trial

Nov. 2, 1998

Licensing opportunity from NIH: antiretroviral agents with unique mechanism of action

Nov. 2, 1998

HIV integrase inhibitors may impart greater efficacy to combination therapies

Oct. 30, 1998

Addition of Remune increases efficacy of HAART in HIV-positive patients

Oct. 29, 1998

Anti-HIV-1 TBZ analogues synthesized and evaluated by European academic group

Oct. 28, 1998

Hughes Institute develops potent and selective d4T analogue as anti-HIV candidate

Oct. 27, 1998

New synthetic anti-HIV compound resembling NNRTIs in development at Nippon Suisan

Oct. 27, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...